エピソード

  • Singapore HSA's New Registration Pathway for Special Access Route (SAR) Devices

    Singapore HSA's New Registration Pathway for Special Access Route (SAR) Devices
    2026/09/06
    Singapore's Health Sciences Authority (HSA) launched a Registration Support Initiative on August 28, 2026, to help transition clinically important medical devices from the Special Access Route (SAR) to full market registration. This episode details the purpose of this new pathway, the eligibility criteria for devices serving small patient populations, the significant evaluation-fee waiver, and the inaugural application deadline of December 31, 2026. We provide practical steps for manufacturers to leverage this opportunity to secure a sustainable, registered supply route in Singapore. Key Questions: - What is Singapore's Special Access Route (SAR) and why is it not a long-term solution for market access? - What is the purpose of the new HSA Registration Support Initiative launched in August 2026? - Which medical devices are eligible to transition from SAR to full registration under this new pathway? - What are the key benefits for manufacturers, including the full waiver of evaluation fees? - What is the critical inaugural application deadline that companies must meet? - What evidence is needed to demonstrate a device's clinical importance for a small patient population in Singapore? - How does prior approval from a comparable overseas regulator impact eligibility for the initiative? - What practical steps should regulatory and market-access teams take now to prepare a submission? Sources: - https://gpc-gateway.com/2026/08/31/singapore-introduces-fee-supported-registration-pathway-for-clinically-important-medical-devices/ How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, combining local expertise with advanced AI to streamline global market access. We act as a local representative in over 30 markets, develop efficient regulatory strategies, and use AI to compile and submit technical dossiers. Our services help you gain and maintain market access through continuous regulatory monitoring and post-market surveillance. Whether you are a startup or a multinational enterprise, Pure Global provides a single, efficient process to access multiple international markets. Learn more about our free AI tools and global database at https://pureglobal.ai, or contact us at info@pureglobal.com and https://pureglobal.com to accelerate your market entry.
    続きを読む 一部表示
    5 分
  • UK MHRA Health Bill Amendments 2026: New Powers for Future Device Regulation

    UK MHRA Health Bill Amendments 2026: New Powers for Future Device Regulation
    2026/09/05
    The UK government has proposed three amendments to the Health Bill, introduced on September 1, 2026, that grant significant new powers to the MHRA. This episode breaks down what these changes—enhanced information sharing, agile regulatory updates via secondary legislation, and the foundation for a future UK-specific device licensing system—mean for medical device manufacturers. We discuss the strategic implications for companies relying on CE marking for UK market access and outline practical steps that regulatory and quality teams should take now to prepare for Great Britain's move toward a sovereign regulatory framework. Key Questions: - What new powers are proposed for the UK MHRA in the 2026 Health Bill? - How will the MHRA's ability to share information with the wider healthcare system change? - What does "agile regulation" mean for medical device manufacturers in the UK? - Is the UK moving away from reliance on the UKCA and CE marks for device approval? - When were these amendments introduced and what is the legislative timeline? - How do these changes affect companies currently using a CE mark for UK market access? - What foundational steps are being taken to create a future UK device licensing system? - What practical actions should regulatory teams take now to prepare for these changes? Sources: - https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill - https://medtech.pharmaintelligence.informa.com/MT151249/MHRA-May-Get-Wider-Device-Licensing-Powers-As-UK-Eyes-New-Regulatory-Regime - https://commonslibrary.parliament.uk/research-briefings/cbp-9999/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying access to over 30 global markets. Our experts develop efficient regulatory strategies, manage technical dossier submissions, and act as your local representative to ensure ongoing compliance. By combining in-country expertise with advanced AI, we help you navigate complex and evolving landscapes like the UK's move toward a sovereign system. Prepare your business for future requirements and accelerate your market entry with our technology-driven solutions. Visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.
    続きを読む 一部表示
    4 分
  • UK MHRA's New Licensing Powers: What the 2026 Health Bill Amendments Mean for Medical Device Manufacturers

    UK MHRA's New Licensing Powers: What the 2026 Health Bill Amendments Mean for Medical Device Manufacturers
    2026/09/04
    This episode explores the significant amendments to the UK Health Bill introduced on September 1, 2026, which grant the MHRA new powers to establish a future medical device licensing regime. We analyze the potential shift from the current system of third-party UK Approved Bodies to a direct licensing model where the MHRA would approve devices. We discuss the long-term implications for manufacturers' market access strategies in Great Britain, who is affected, and the practical steps regulatory teams should consider for this evolving landscape. Key Questions: - What are the new powers granted to the UK MHRA under the 2026 Health Bill amendments? - How could the UK's medical device approval process change from a third-party model to a direct licensing system? - Who is affected by this potential new regulatory framework in Great Britain? - What is the significance of the September 1, 2026 date for medical device manufacturers? - How does this proposed change impact long-term market access strategies for the UK? - What are the potential benefits and challenges of an MHRA-led direct licensing regime? - What practical steps should regulatory teams take now to prepare for these future changes? - Why is it crucial to monitor MHRA consultations and announcements moving forward? Sources: - https://www.gov.uk/government/news/mhra-regulatory-reform-amendments-tabled-in-governments-health-bill--2 - https://medtech.citeline.com/MT153453/MHRA-May-Get-Wider-Device-Licensing-Powers-As-UK-Eyes-New-Regulatory-Regime How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative and help you navigate complex regulatory landscapes like the evolving UK system. Our experts, combined with advanced AI tools, develop efficient strategies for market approval and maintain compliance through post-market surveillance. Whether you're a startup or a multinational, we can help you prepare for changes like the MHRA's potential shift to direct licensing. Visit https://pureglobal.com, email us at info@pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your market entry.
    続きを読む 一部表示
    5 分
  • UK MHRA Non-Compliant Devices: DSI/2026/007 and Supply Chain Risks

    UK MHRA Non-Compliant Devices: DSI/2026/007 and Supply Chain Risks
    2026/09/03
    The UK's MHRA has issued Device Safety Information notice DSI/2026/007, warning of non-compliant medical devices on the UK market lacking valid UKCA or CE marking. This episode breaks down the immediate actions required for healthcare providers and suppliers, such as quarantining suspect products and reporting to the MHRA. We also explore the critical implications for manufacturers, focusing on the need for enhanced post-market surveillance and rigorous supply chain oversight to prevent patient risk and ensure compliance with UK MDR 2002. Key Questions: - What is the significance of the UK MHRA's Device Safety Information notice DSI/2026/007? - Which devices are affected by this non-compliance warning? - What immediate steps must UK healthcare providers and distributors take? - How does this notice impact a manufacturer's post-market surveillance obligations? - Why is supply chain oversight more critical than ever for devices in the UK? - What are the risks of having non-compliant devices on the market? - How can manufacturers audit their UK distribution channels effectively? - What role does UDI and proper labeling play in preventing this issue? - What are the long-term regulatory implications for market access in the UK? Sources: - https://www.gov.uk/government/publications/mhra-safety-roundup-august-2026 How Pure Global can help: Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you access global markets faster. Our experts provide strategic guidance on UKCA marking, post-market surveillance, and supply chain management to ensure ongoing compliance. We act as your local representative and use advanced AI to streamline technical dossier preparation and submission. Whether you're a startup or a multinational, we can help you navigate the complexities of the UK market. Visit https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and device database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分
  • Australia TGA Consultation on Medical Device Information Sharing: What Sponsors Need to Know

    Australia TGA Consultation on Medical Device Information Sharing: What Sponsors Need to Know
    2026/09/02
    Australia's Therapeutic Goods Administration (TGA) has launched a consultation on proposals to increase the public sharing of medical device information. This episode breaks down the TGA's initiative, which was announced on August 13, 2026, and explores its potential impact on manufacturers and sponsors. We discuss the types of information that may become public, the implications for post-market surveillance and data management, and the crucial feedback deadline of October 2, 2026. Learn the practical steps your team should take now to prepare for a future of greater transparency in the Australian market. Key Questions: - What specific information does the TGA propose to make public about medical devices? - How will these changes impact the obligations of Australian sponsors and manufacturers? - What is the deadline for providing feedback on this important TGA consultation? - How could increased transparency affect post-market surveillance and reporting requirements? - What steps should regulatory teams take now to prepare for these potential changes? - Will commercially sensitive information be protected under the new proposals? - How does this Australian initiative align with global trends in medical device transparency? - What are the TGA's stated goals for improving the sharing of medical device information? Sources: - https://www.tga.gov.au/news/news/consultation-improving-sharing-information-about-medical-devices - https://www.tga.gov.au/resources/consultations/consultation-sharing-more-information-about-medical-devices How Pure Global can help: Pure Global helps MedTech and IVD companies access global markets faster. Navigating regulatory shifts like the TGA's proposal for greater transparency requires local expertise and a proactive strategy. We act as a local representative in Australia and over 30 other markets, providing continuous regulatory monitoring to keep you ahead of changes. Our experts and AI-powered tools streamline the creation of technical dossiers, manage post-market surveillance, and help you develop a robust strategy for compliance and market access. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.
    続きを読む 一部表示
    4 分
  • Health Canada Special Access Program: New Application Process for Medical Devices

    Health Canada Special Access Program: New Application Process for Medical Devices
    2026/09/01
    Health Canada has modernized the application process for its Medical Devices Special Access Program (SAP) as of August 24, 2026. This episode details the two key changes: the introduction of a new accessible PDF application form and a new secure online submission method. We explore Health Canada's goals to reduce errors, improve data security, and accelerate review times for unauthorized devices needed for patients with serious conditions, outlining the practical steps for healthcare professionals and manufacturers. Key Questions: - What is Health Canada's Special Access Program for medical devices? - What specific changes were announced for the SAP application process on August 24, 2026? - Why did Health Canada introduce a new PDF application form? - What are the benefits of the new secure online submission method? - Who is primarily affected by these SAP application changes? - How can manufacturers and healthcare professionals prepare for this new process? - What common errors is the new system designed to prevent? - What practical steps should regulatory teams take right now? Sources: - https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/announcements.html - https://www.smart-mdr.com/health-canada-announces-changes-to-special-access-program-application-process-for-medical-devices/ How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies achieve faster global market access. We act as your local representative in over 30 markets, including Canada, developing efficient regulatory strategies and using advanced AI to compile and manage technical submissions. Our experts ensure ongoing compliance through post-market surveillance and continuous regulatory monitoring. For support with the Canadian SAP process or other market access challenges, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and extensive device database at https://pureglobal.ai.
    続きを読む 一部表示
    6 分
  • UK MHRA ResMed Astral Alert: Ventilator Safety Actions for NatPSA/2026/004/MHRA

    UK MHRA ResMed Astral Alert: Ventilator Safety Actions for NatPSA/2026/004/MHRA
    2026/08/31
    The UK's MHRA issued National Patient Safety Alert NatPSA/2026/004/MHRA on August 17, 2026, for ResMed Astral 100 and 150 ventilators manufactured before October 2024. A faulty internal supercapacitor can leak, causing the device to shut down unexpectedly and risking serious injury or death. This episode details the specific device fault, the risks to patients, and the mandatory actions required by the MHRA for healthcare providers and manufacturers. We focus on the critical importance of post-market surveillance and immediate risk mitigation for life-sustaining devices. Key Questions: - What is the specific defect in ResMed Astral ventilators identified by the MHRA? - Which device models and manufacturing dates are covered by NatPSA/2026/004/MHRA? - What are the immediate risks to patients in hospital and home care settings? - What actions must healthcare providers take to ensure patient safety? - How does this alert impact post-market surveillance obligations for manufacturers of life-sustaining devices? - What is the role of backup ventilation for affected patients? - How can teams document their response to this MHRA safety alert for compliance? - What lessons can be learned about component traceability and supplier quality management? Sources: - https://www.gov.uk/alerts-and-recalls/national-patient-safety-alert-resmed-astral-100-and-150-ventilators-potential-for-patient-harm-due-to-unexpected-interruption-of-ventilation-therapy-natpsa-2026-004-mhra - https://dispex.net/news-alerts/national-patient-safety-alert-resmed-astral-100-and-150-ventilators/ - https://www.gov.uk/government/publications/mhra-safety-roundup-august-2026/mhra-safety-roundup-august-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech companies, ensuring products meet safety and performance standards from development to post-market surveillance. Our experts help you establish robust post-market surveillance systems, manage incident reporting, and execute field safety corrective actions efficiently. With local representation in over 30 markets, including the UK, we act as your in-country contact with authorities like the MHRA, ensuring timely communication and compliance. Leverage our AI-powered tools and global database at https://pureglobal.ai to streamline your regulatory processes and maintain market access. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more.
    続きを読む 一部表示
    5 分
  • China NMPA Medical Device Approval: Analyzing the August 12, 2026 Batch

    China NMPA Medical Device Approval: Analyzing the August 12, 2026 Batch
    2026/08/30
    China's NMPA announced the approval of 122 medical devices on August 12, 2026, including many from leading international manufacturers such as Medtronic, Roche, and Siemens. This episode breaks down this significant regulatory event, analyzing the types of devices approved—from cardiovascular and IVDs to imaging and surgical tools. We explore what this large batch of approvals reveals about the NMPA's current review priorities, the opportunities available for foreign manufacturers, and the practical steps your regulatory and market access teams should take to leverage these insights for a successful China strategy. Key Questions: - What does the NMPA's latest batch of 122 device approvals mean for the Chinese market? - Which types of medical devices are being prioritized by Chinese regulators? - How can foreign manufacturers like Medtronic and Siemens find success in China? - What do these approvals reveal about the NMPA's review timelines and pathways? - Are there new opportunities for cardiovascular, IVD, or imaging devices in China? - What practical steps should my regulatory team take in response to this news? - How can we leverage this information for our China market access strategy? - Does this signal a shift in China's policy towards imported medical devices? Sources: - https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH02KbGyLdFMQfPN0_gVaWwc8YCTOtfEC-dbM5f0Jt-IBAMMrphnYEi5w8UKI1s8OoNRKu7vlRJ9ardRwtE9szhk3WH0WRsVoYrdgpq5qeq__bcflDwDPi7xcUqnvbxgL3S_3P1koNiqAyRZRhRR34= How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies seeking to access the Chinese market. Our in-country experts in China and advanced AI technology streamline the NMPA registration process, from developing a robust regulatory strategy and compiling technical dossiers to managing local type testing and post-market surveillance. We act as your local representative, ensuring seamless communication with the NMPA and helping you navigate complex requirements to get your product to market faster. To learn more about our China market access solutions, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our free AI tools and global device database at https://pureglobal.ai.
    続きを読む 一部表示
    5 分